Place, Space and Memory in the Old Jewish East End of London: an Archaeological Biography of Sandys Row Synagogue, Spitalfields and its Wider Context

Sandys Row (London E1) is the only functioning Ashkenazi (Eastern European Jewish) Synagogue in Spitalfields and the oldest still functioning Ashkenazi synagogue in London. Located in an area, which from the mid­late nineteenth century until WWII was the centre of London’s Jewish population, it is one of the last surviving witnesses to a once vibrant and dynamic heritage that has now virtually disappeared. This area has been the first port of call for refugees for centuries, starting with French Protestant Huguenots in the eighteenth century, then Jews fleeing economic hardship and pogroms in Eastern Europe in the nineteenth century followed by Bangladeshi Muslims in the twentieth century. Using a broadly archaeological analysis based very closely on the sort of practice widely used in church archaeology, the authors argue that much can be inferred about wider social and cultural patterns from a study of architectural space at Sandys Row and its associated material culture. This is the first such archaeological study undertaken of a synagogue in Britain and offers a new perspective on wider issues regarding the archaeological definition of religious practice and religious material culture

Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women - a randomized trial

BackgroundIt is not known whether premenopausal women who report low sexual satisfaction and have low circulating testosterone levels will benefit from testosterone therapy.ObjectiveTo evaluate the effects of exogenous testosterone in premenopausal women reporting diminished sexual function.DesignRandomized, double-blind, placebo-controlled, dose-ranging trial.Setting6 Australian medical centers.Patients261 women age 35 to 46 years who reported a decrease in satisfying sexual activity relative to their younger years and had a morning serum free testosterone level less than 3.8 pmol/L (Intervention3 different doses of testosterone administered by a metered-dose transdermal spray for 16 weeks or placebo.MeasurementsThe primary outcome was the mean number of self-reported satisfactory sexual events (SSEs) over 28 days at week 16. The frequency of SSEs, total number of sexual events (every 4 weeks), scores from the modified Sabbatsberg Sexual Self-Rating Scale and the Psychological General Well-Being Index, and safety variables were also measured.ResultsThe number of SSEs increased during the treatment period in the active treatment groups and the placebo group. The mean number of SSEs over 28 days at week 16 was statistically significantly greater for women treated with the intermediate dose of testosterone therapy (one 90-microL spray) than for women treated with placebo. The least-squares mean was 2.48 versus 1.70 SSEs, respectively (event rate ratio, 1.49 [95% CI, 1.01 to 2.18]; P = 0.04). The frequency of SSEs in women treated with low and high doses of testosterone did not differ from that in women who took placebo. The rate ratios based on the least-squares mean rates of SSEs during weeks 4 to 16 for each treatment group showed statistically significant or borderline significant increases in all testosterone groups compared with the placebo group. The rate ratios for the one 56-microL spray, one 90-microL spray, and two 90-microL sprays treatment groups were 1.34 (CI, 0.97 to 1.85; P = 0.081), 1.48 (CI, 1.07 to 2.06; P = 0.018), and 1.38 (CI, 1.00 to 1.92; P = 0.052), respectively. At week 16, 95% of women treated with the one 90-microL dose had a free testosterone level less than the upper limit of the reference range for women. The most frequently reported adverse event was hypertrichosis, which was dose-related and mostly confined to the application site. No clinically relevant changes in blood test values, serum biochemical variables, or vital signs occurred.LimitationThe study duration was short, and the placebo effect was strong.ConclusionA daily 90-microL dose of transdermal testosterone improves self-reported sexual satisfaction for premenopausal women with reduced libido and low serum-free testosterone levels by a mean of 0.8 SSE per month. The rate of SSEs with higher and lower testosterone doses did not differ from that with placebo.Susan Davis, Mary-Anne Papalia, Robert J. Norman, Sheila O'Neill, Margaret Redelman, Margaret Williamson, Bronwyn G.A. Stuckey, John Wlodarczyk, Karen Gard'ner, and Andrew Humberston